Martin Heydon (Kildare South, Fine Gael) | Oireachtas source

I thank Senator McGreehan for raising what is a very important issue. It is timely, given the significance of this month for promoting the risk in this area.

The use of genetics and genetic testing in cancer care has developed and changed in recent years. The focus has shifted from that of prevention to a more holistic approach to cancer care. Developments in genetic and genomic medicine mean a greater understanding of the cancer a person has. This, in turn, leads to more precise diagnosis and treatment.

The potential for cancer genetics services is identified in the National Cancer Strategy 2017-2026. In line with recommendations in the strategy, a model of care for hereditary cancer was launched in June of this year. This will inform the development of services for the identification and management of people with an inherited cancer predisposition.

There have been several recent positive developments in genetic and genomic medicine in Ireland. The national strategy for accelerating genetic and genomic medicine in Ireland was published by the Department of Health and the HSE at the end of 2022. In 2023, the Government allocated €2.7 million to the implementation of this strategy. This allocation included the establishment of the national office of genetics and genomics and the appointment of front-line staff. Work under this strategy will enable and facilitate the implementation of the model of care for hereditary cancer. A steering group for the implementation of the national strategy for accelerating genetic and genomic medicine in Ireland was set up in April. This multi-stakeholder group is responsible for ensuring the effective delivery of the strategy’s implementation.

In terms of broader supports for patients at high risk of developing cancer, the national cancer strategy provides for the further development of a programme for hereditary cancers. This will ensure evaluation, counselling, testing and risk reduction interventions are available, as appropriate, and that services are available to patients on the basis of need. Genetic counsellors continue to be recruited to the cancer genetics services, providing support to people on their genetic testing results.

The Government’s commitment to the implementation of the national cancer strategy is evidenced by significant investment in recent years. New development funding of €20 million was allocated in 2021 and a further €20 million was provided in 2022. This funding has facilitated work in a number of areas affecting those with a BRCA gene alteration. This includes the completion of a needs assessment for those with a BRCA gene alteration, the development of a GP referral guideline for breast cancer family history, including pathways from primary to secondary care, and the development of online training for healthcare professionals delivering genetic testing embedded in oncology services. This funding has also facilitated the development of recommendations on universal tumour testing in certain types of cancer. This focuses on identifying possible Lynch syndrome, an inherited condition which causes people to have a higher risk of developing certain colorectal cancers.

The national cancer control programme will shortly commence active data collection at the locations currently providing preventative surgeries for people at high risk of developing cancer. This review will focus on patient activity and available resources.